Search for other papers by Kathrin R Frey in
Google Scholar
PubMed
Search for other papers by Tina Kienitz in
Google Scholar
PubMed
Search for other papers by Julia Schulz in
Google Scholar
PubMed
Search for other papers by Manfred Ventz in
Google Scholar
PubMed
Search for other papers by Kathrin Zopf in
Google Scholar
PubMed
Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
study enrolment (visit1), after 2 and 5 years (visit2 and visit3, respectively), BMD was assessed by DXA scan, and all clinical data, including hormone replacement therapies, DHEA and bisphosphonate therapies and changes were documented. Fracture
Search for other papers by Sarantis Livadas in
Google Scholar
PubMed
Search for other papers by Christina Bothou in
Google Scholar
PubMed
Search for other papers by Justyna Kuliczkowska-Płaksej in
Google Scholar
PubMed
Search for other papers by Ralitsa Robeva in
Google Scholar
PubMed
Search for other papers by Andromahi Vryonidou in
Google Scholar
PubMed
Search for other papers by Jelica Bjekic Macut in
Google Scholar
PubMed
Search for other papers by Ioannis Androulakis in
Google Scholar
PubMed
Search for other papers by Milica Opalic in
Google Scholar
PubMed
Search for other papers by Zadalla Mouslech in
Google Scholar
PubMed
Search for other papers by Andrej Milewicz in
Google Scholar
PubMed
Search for other papers by Alessandra Gambineri in
Google Scholar
PubMed
Search for other papers by Dimitrios Panidis in
Google Scholar
PubMed
Search for other papers by Djuro Macut in
Google Scholar
PubMed
Laboratories, Webster, TX, USA). DHEAS serum levels were measured by DSL DHEAS RIA kit (Diagnostic Systems Laboratories). LH and FSH were measured using the LHsp and FSH IRMA kits from Biosource Technologies. E2 was measured by RIA (Immunometrics, London, UK
Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain
Search for other papers by Pablo Abellán-Galiana in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo-Montañana in
Google Scholar
PubMed
Search for other papers by Pedro Riesgo-Suárez in
Google Scholar
PubMed
Search for other papers by Marcelino Pérez-Bermejo in
Google Scholar
PubMed
Search for other papers by Celia Ríos-Pérez in
Google Scholar
PubMed
Search for other papers by José Gómez-Vela in
Google Scholar
PubMed
BM . The value of perioperative levels of ACTH, DHEA, and DHEA-S and tumor size in predicting recurrence of Cushing disease . Journal of Clinical Endocrinology and Metabolism 2018 477 – 485 . ( https://doi.org/10.1210/jc.2017-01797 ) 41 Asuzu
Department of Medical Sciences, Occupational and Environmental Medicine, Uppsala University, Uppsala, Sweden
Search for other papers by Johanna Christina Penell in
Google Scholar
PubMed
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA
Search for other papers by Mark M Kushnir in
Google Scholar
PubMed
Search for other papers by Lars Lind in
Google Scholar
PubMed
Search for other papers by Jonatan Bergquist in
Google Scholar
PubMed
Department of Chemistry – BMC, Analytical Chemistry, Uppsala University, Uppsala, Sweden
Search for other papers by Jonas Bergquist in
Google Scholar
PubMed
Search for other papers by P Monica Lind in
Google Scholar
PubMed
Search for other papers by Tord Naessen in
Google Scholar
PubMed
Alzheimer’s disease and impaired cognitive function ( 8 ). The levels of sex hormones may also be related to BMI), and diabetes status ( 4 ), prevalent cardiovascular disease (CVD) ( 9 ), and vascular aging in elderly women and men ( 10 ). Higher
Search for other papers by Jana Ernst in
Google Scholar
PubMed
Search for other papers by Katharina Gert in
Google Scholar
PubMed
Search for other papers by Frank Bernhard Kraus in
Google Scholar
PubMed
Search for other papers by Ulrike Elisabeth Rolle-Kampczyk in
Google Scholar
PubMed
Search for other papers by Martin Wabitsch in
Google Scholar
PubMed
Search for other papers by Faramarz Dehghani in
Google Scholar
PubMed
Search for other papers by Kristina Schaedlich in
Google Scholar
PubMed
II, DHEA-S, Elecsys Progesterone III, Elecsys Testosterone II and Elecsys Estradiol III, Roche Diagnostics) on a Roche Cobas e602 Analyzer, also being part of the fully automated Roche Cobas 8000 platform. All analyses on the Roche Cobas Analyzers
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Milène Tetsi Nomigni in
Google Scholar
PubMed
Search for other papers by Sophie Ouzounian in
Google Scholar
PubMed
Search for other papers by Alice Benoit in
Google Scholar
PubMed
Search for other papers by Jacqueline Vadrot in
Google Scholar
PubMed
Search for other papers by Frédérique Tissier in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sylvie Renouf in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Hervé Lefebvre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sophie Christin-Maitre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Estelle Louiset in
Google Scholar
PubMed
hyperandrogenism (5, 6) . They are commonly associated with high testosterone levels (7, 8) . High plasma levels of testosterone associated with normal dehydroepiandrosterone sulfate (DHEAS) concentration are indicative of ovarian hyperthecosis or androgen
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
Search for other papers by Elisabeth Lerchbaum in
Google Scholar
PubMed
(vitamin D group) vs 29.6 ± 1.7 years (placebo group) 40.7 ± 2.2 nmol/L (vitamin D group) vs 42.4 ± 4.2 nmol/L (placebo group) Serum TGF-β1, sENG, lipid profile, testosterone, DHEA-S, insulin resistance 8 weeks 50,000 IU cholecalciferol weekly vs
Polish Mother’s Memorial Hospital–Research Institute, Lodz, Poland
Search for other papers by Krzysztof C Lewandowski in
Google Scholar
PubMed
Search for other papers by Justyna Płusajska in
Google Scholar
PubMed
Search for other papers by Wojciech Horzelski in
Google Scholar
PubMed
Search for other papers by Ewa Bieniek in
Google Scholar
PubMed
Polish Mother’s Memorial Hospital–Research Institute, Lodz, Poland
Search for other papers by Andrzej Lewiński in
Google Scholar
PubMed
Androstenedione DHEA-S HOMA 0.155 0.124 0.0327 IRI (Belfiore) 0.139 0.0536 0.0825 QUICKI −0.152 −0.124 −0.0382 McAuley −0.150 −0.122 −0.0358 Matsuda −0.149 −0.110 −0.0448 Stumvoll 0–120 −0
Search for other papers by Gregory Knowles in
Google Scholar
PubMed
Search for other papers by Emily Warmington in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Lisa M Shepherd in
Google Scholar
PubMed
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
Search for other papers by Jonathan M Hazlehurst in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Anne de Bray in
Google Scholar
PubMed
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Medical Research Council London Institute of Medical Sciences, London, UK
Search for other papers by Wiebke Arlt in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Introduction Primary adrenal insufficiency (PAI) is characterised by inadequate steroid hormone secretion caused by intrinsic adrenal cortex disease ( 1 ). The most common causes of PAI are Addison’s disease (AD), usually resulting from
Division of Endocrinology, Mid and South Essex NHS Trust, Broomfield, UK
Search for other papers by Saroj Kumar Sahoo in
Google Scholar
PubMed
Search for other papers by Jayakrishnan C Menon in
Google Scholar
PubMed
Search for other papers by Nidhi Tripathy in
Google Scholar
PubMed
Search for other papers by Monalisa Nayak in
Google Scholar
PubMed
Search for other papers by Subhash Yadav in
Google Scholar
PubMed
-COVID syndrome, n (%) 12 (100) 36 (47) 0.00 S. morning cortisol, 0 min (nmol/L) 69 (45–125) 275 (91–396) 0.01 S. peak cortisol (nmol/L) 246 (130–348) 615 (458–754) 0.00 S. DHEAS (µmol/L) 3.82 (0.75–6.56) 2.37 (1